capecitabine

Adult Dosing .

Dosage forms:  TAB: 150 mg, 500 mg

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

stage III colon CA, adjuvant tx

[monotherapy]

Dose: 1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Max: 8 cycles; Info: give after meals; do not cut/crush/chew tab

[combo w/ oxaliplatin-containing regimen]

Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Max: 8 cycles; Info: give after meals; do not cut/crush/chew tab

rectal CA, locally advanced, perioperative tx

[combo w/ XRT]

Dose: 825 mg/m^2/dose PO bid; Info: give after meals; do not cut/crush/chew tab

[chemo combo tx w/o XRT]

Dose: 1250 mg/m^2/dose PO bid; Info: give after meals; do not cut/crush/chew tab

colorectal CA, unresectable or metastatic

[monotherapy]

Dose: 1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: give after meals; do not cut/crush/chew tab

[combo w/ oxaliplatin]

Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: give after meals; do not cut/crush/chew tab

breast CA, advanced or metastatic

[monotherapy]

Dose: 1000-1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for paclitaxel- and anthracycline-resistant dz; give after meals; do not cut/crush/chew tab

[combo w/ docetaxel]

Dose: 1000-1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for anthracycline-resistant dz; give after meals; do not cut/crush/chew tab

[combo w/ lapatinib (off-label)]

Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ HER2-positive dz who have received prior tx, incl. anthracycline, taxane, and trastuzumab; give after meals; do not cut/crush/chew tab

[combo w/ neratinib (off-label)]

Dose: 750 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ HER2-positive dz who have received 2 or more anti-HER2 based regimens; give after meals; do not cut/crush/chew tab

gastric CA

[unresectable or metastatic dz]

Dose: 625 mg/m^2/dose PO bid on days 1-21 of 21-day cycle for up to 8 cycles; Alt: 850-1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab

[HER2-positive metastatic dz, first-line tx]

Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ gastric or gastroesophageal junction adenocarcinoma; part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab

esophageal CA

[unresectable or metastatic dz]

Dose: 625 mg/m^2/dose PO bid on days 1-21 of 21-day cycle for up to 8 cycles; Alt: 850-1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab

[HER2-positive metastatic dz, first-line tx]

Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ gastroesophageal junction adenocarcinoma; part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab

pancreatic CA, adjuvant tx

[830 mg/m^2/dose PO bid on days 1-21 of 28-day cycle]

Max: 6 cycles; Info: give w/ gemcitabine; give after meals; do not cut/crush/chew tab

renal dosing

[adjust dose amount]

CrCl 30-50: decr. usual dose by 25%; CrCl <30: decr. usual dose, amount not defined

HD/PD: not defined

hepatic dosing

[see below]

hepatic impairment: not defined, caution advised

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.